NLR and PLR Levels Following PENG Block in Hip Arthroplasty
CompletedPhase 4NCT07023107
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Effect of PENG block on NLR and PLR following hip arthroplasty
Study details
- Official title
- Pericapsular Nerve Group Block Mitigates Surgical Stress and Enhances Analgesia in Total Hip Arthroplasty: A Randomized Controlled Trial
- Conditions
- Hip Arthropathy
- Hip Osteoarthritis
- Hip Pain Chronic
- Interventions
- Drug: 0.9% Sodium Chloride Injection
- Drug: Ropivacaine 0.2% Injectable Solution
- Sponsor
- Poznan University of Medical Sciences
- Start date
- 2025-06-16
- Primary completion
- 2025-12-09
- Sex
- All
- Age range
- from 60 Years to 100 Years
- Results posted
- No results posted in this snapshot
- Countries
- Poland
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients with ASA classification I-III * Aged 60-100 years * Who will be scheduled for hip arthroplasty under spinal anesthesia Exclusion Criteria: * Patients who have a history of bleeding diathesis * Take anticoagulant therapy * History of chronic pain before surgery * Multiple trauma * patients unable to assess their pain (dementia) * patients operated under general anesthesia * patients having an infection in the region of the procedure * the patient who does not accept the procedure
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07023107